Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 07 2022 - 4:05PM
Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, announced today
that Rachel Haurwitz, Ph.D., Caribou’s president and chief
executive officer, will participate in a fireside chat at the SVB
Leerink 11th Annual Global Healthcare Conference on Thursday,
February 17th, at 2:20 pm ET.
A live webcast of the discussion will be accessible via
Caribou’s website on the Events page. The archived webcast will be
available on the Caribou website for 30 days after the event.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Type II CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems
occasionally edit unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
chRDNAs (pronounced “chardonnays”), RNA-DNA hybrid guides that
direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of the chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its proprietary Cas12a chRDNA
technology, enables superior precision to develop cell therapies
that are specifically engineered for enhanced persistence. Caribou
is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell
therapies for the treatment of patients with hematologic
malignancies and solid tumors.
Follow us @CaribouBio and visit www.cariboubio.com.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Caribou Biosciences,
Inc. Contact:Amy Figueroa, CFAInvestor
Relations and Corporate
Communicationsafigueroa@cariboubio.comInvestors:Elizabeth
Wolffe, Ph.D., and Sylvia WheelerWheelhouse
LSAlwolffe@wheelhouselsa.comswheeler@wheelhouselsa.comMedia: |
|
Greg
KelleyOgilvygregory.kelley@ogilvy.com617-461-4023 |
|
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024